Amiloride hydrochloride(CAS:2016-88-8)

Amiloride Hydrochloride, CAS 2016-88-8, is a classic and stable high-efficiency potassium-sparing diuretic API. As a special diuretic that exerts efficacy independent of aldosterone, it occupies an irreplaceable position in clinical compound diuretic medication and pharmaceutical production. Different from common potassium-excreting diuretics such as furosemide and torasemide, Amiloride Hydrochloride features unique sodium excretion and potassium retention effects, which can effectively avoid hypokalemia and electrolyte disorders caused by long-term use of traditional diuretics. With stable physical and chemical properties, high purity and low impurity content, it fully meets international pharmacopoeia standards and is widely used in the production of oral tablets and other cardiovascular pharmaceutical preparations.

In terms of pharmacological mechanism, Amiloride Hydrochloride precisely acts on the epithelial cells of renal distal convoluted tubules and collecting ducts. It specifically blocks sodium ion channels and inhibits the sodium-potassium and sodium-hydrogen exchange processes in the human body. While accelerating the excretion of excess sodium, chloride and water to eliminate water-sodium retention, it effectively reduces the loss of potassium and hydrogen ions, achieving dual effects of efficient diuresis and stable potassium retention. Its most prominent advantage is aldosterone-independent efficacy, which is not affected by human hormone levels and completely avoids endocrine disorders and hormone accumulation side effects. The drug takes effect steadily within 2 hours after oral administration, reaches peak efficacy in 6 to 10 hours, and lasts for 24 to 48 hours, enabling long-term and stable treatment without frequent medication.

Clinically, Amiloride Hydrochloride has extensive and targeted application values. Used alone, it provides mild diuretic and auxiliary antihypertensive effects for mild edema and hypokalemia patients. Its core application lies in combined medication. When matched with thiazide and loop diuretics, it produces significant pharmacological synergism, greatly improving the diuretic and detumescent effect while completely offsetting potassium loss, fundamentally preventing hypokalemia and maintaining electrolyte balance. It is widely used in the treatment of systemic edema and pulmonary edema caused by congestive heart failure, hepatic ascites and edema induced by liver cirrhosis, and renal edema caused by acute and chronic kidney diseases. Moreover, it is the preferred auxiliary raw material for refractory hypokalemia, which can effectively correct electrolyte imbalance and stabilize cardiovascular function.

In terms of safety and industrial application, Amiloride Hydrochloride has excellent tolerance with extremely low adverse reaction rates under conventional therapeutic doses. Only occasional mild gastrointestinal discomfort and slight electrolyte fluctuations may occur, which can be relieved by dosage adjustment without liver and kidney accumulation toxicity or hormonal side effects. It is suitable for elderly patients and patients with mild renal impairment, supporting individualized medication. At present, Amiloride Hydrochloride adopts mature synthetic technology with stable batch quality, controllable cost and large-scale production capacity. With the comprehensive advantages of long-lasting efficacy, high safety and strong compatibility, it has always been an essential API for clinical combined diuretic treatment, maintaining stable market demand and broad development prospects in the treatment of cardiovascular, renal and liver diseases worldwide.